Andrew Felts, PhD

Principal Scientist, Medicinal Chemistry

Andrew Felts, Ph.D., Principal Scientist, Medicinal Chemistry, is responsible for the design of novel non-hallucinogenic psychoplastogens for the treatment of mental health and CNS disorders.

Andrew brings over 15 years of CNS drug discovery experience working in the field of GPCR allosteric modulation (specifically the glutamate and muscarinic receptors). As an Associate Director of Medicinal Chemistry for the Warren Center for Neuroscience Drug Discovery in Nashville Tennessee Andrew progressed a multitude of projects delivering many pre-clinical candidates and successful IND filings. With this experience, Andrew is helping to drive the science at Delix to identify novel psychoplastogens and progress them to the clinic.

During his scientific career, Andrew has been co-inventor on over 40 international and U.S. patents as well as co-author on over 40 peer-reviewed publications. He received his Ph.D. in Chemistry under the direction of Larry Marnett at Vanderbilt University and his B.S. in Chemistry from Florida State University. Andrew also received a B.A. in Psychology at the University of Tennessee at Knoxville.